Pancreatic Cancer Research

ResearcherUniversitätsmedizin RostockActive in the last 2 years

Dietmar Zechner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2075-7540; OpenAlex author ID A5002631983. Sources: OpenAlex.

Their work

Papers
21 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 4 papers · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper

Papers 21

  1. Burrowing Behavior as Robust Parameter for Early Humane Endpoint Determination in Murine Models for Pancreatic Cancer. Co-author DOI 10.3390/ani15091241↗
  2. Effects of triggers of senescence and senolysis in murine pancreatic cancer cells. Co-author DOI 10.1016/j.hbpd.2024.06.001↗
  3. Evidence-Based Severity Assessment of Animal Models for Pancreatic Cancer. Co-author DOI 10.3390/biomedicines12071494↗
  4. Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. Last author DOI 10.3390/cancers16101901↗
  5. Uncoupling protein 2 deficiency of non-cancerous tissues inhibits the progression of pancreatic cancer in mice. Co-author DOI 10.1016/j.hbpd.2022.12.003↗
  6. Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. Last author DOI 10.1371/journal.pone.0266601↗
  7. Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.3390/cancers14184467↗
  8. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.3390/ijms23084295↗
  9. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell L… Co-author DOI 10.3390/ijms23084409↗
  10. Voluntary wheel running behaviour as a tool to assess the severity in a mouse pancreatic cancer model. Co-author DOI 10.1371/journal.pone.0261662↗
  11. Benefits of non-invasive methods compared to telemetry for distress analysis in a murine model of pancreatic cancer. Last author DOI 10.1016/j.jare.2019.09.002↗
  12. Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells. Last author DOI 10.21873/anticanres.13936↗
  13. Metformin and LW6 impairs pancreatic cancer cells and reduces nuclear localization of YAP1. Last author DOI 10.7150/jca.33029↗
  14. LW6 enhances chemosensitivity to gemcitabine and inhibits autophagic flux in pancreatic cancer. Last author DOI 10.1016/j.jare.2019.04.006↗
  15. α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway. Last author DOI 10.1016/j.cellsig.2018.03.015↗
  16. Blocking Autophagy in Cancer-Associated Fibroblasts Supports Chemotherapy of Pancreatic Cancer Cells. Last author DOI 10.3389/fonc.2018.00590↗
  17. Metformin Inhibits Gemcitabine Induced Apoptosis in Pancreatic Cancer Cell Lines. Co-author DOI 10.7150/jca.17972↗
  18. Analysis of Axin2 expression and function in murine models for pancreatic cancer. Co-author DOI 10.1186/s13578-016-0116-4↗
  19. Impact of diabetes type II and chronic inflammation on pancreatic cancer. Co-author DOI 10.1186/s12885-015-1047-x↗
  20. Characterization of novel carcinoma cell lines for the analysis of therapeutical strategies fighting pancreatic cancer. Co-author DOI 10.1186/s13578-015-0038-6↗
  21. Risk factors for pancreatic ductal adenocarcinoma specifically stimulate pancreatic duct glands in mice. Last author DOI 10.1016/j.ajpath.2012.11.016↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brigitte Vollmar · 16 shared papers, 2013–2025 · strength 1.90
  2. Simone Kumstel · 9 shared papers, 2018–2025 · strength 1.22
  3. Tim Schreiber · 4 shared papers, 2022–2025 · strength 0.78
  4. Robert Jaster · 5 shared papers, 2018–2024 · strength 0.77
  5. Hugo Murua Escobar · 5 shared papers, 2022–2024 · strength 0.74
  6. Xianbin Zhang · 6 shared papers, 2018–2022 · strength 0.66
  7. Yixuan Ma · 4 shared papers, 2022–2024 · strength 0.59
  8. Benjamin Schulz · 3 shared papers, 2022–2025 · strength 0.59
  9. Maria Schönrogge · 5 shared papers, 2016–2022 · strength 0.55
  10. Edgar Heinz Uwe Wendt · 4 shared papers, 2018–2022 · strength 0.50
  11. Jakob Brandstetter · 2 shared papers, 2024–2025 · strength 0.44
  12. Frank Ulrich Weiß · 3 shared papers, 2022 · strength 0.40
  13. Markus M. Lerch · 3 shared papers, 2022 · strength 0.40
  14. Georg Fuellen · 2 shared papers, 2023–2024 · strength 0.38
  15. Denis Revskij · 2 shared papers, 2023–2024 · strength 0.38
  16. Florian Bürtin · 3 shared papers, 2015–2017 · strength 0.21
  17. Olaf Wolkenhauer A · 1 shared paper, 2023 · strength 0.15
  18. Nora Weegh · 1 shared paper, 2021 · strength 0.12
  19. Christine Häger · 1 shared paper, 2021 · strength 0.12
  20. Peng Gong · 1 shared paper, 2020 · strength 0.12
  21. Peng Gong · 1 shared paper, 2019 · strength 0.11
  22. Lars Ivo Partecke · 1 shared paper, 2015 · strength 0.06
  23. Alexej Bobrowski · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.